| Inositol pyrophosphates inhibit Akt signaling, thereby regulating insulin sensitivity and weight gain A Chakraborty, MA Koldobskiy, NT Bello, M Maxwell, JJ Potter, KR Juluri, ... Cell 143 (6), 897-910, 2010 | 392 | 2010 |
| Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase S Kim, SF Kim, D Maag, MJ Maxwell, AC Resnick, KR Juluri, ... Cell metabolism 13 (2), 215-221, 2011 | 162 | 2011 |
| Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB D Maag, MJ Maxwell, DA Hardesty, KL Boucher, N Choudhari, AG Hanno, ... Proceedings of the National Academy of Sciences 108 (4), 1391-1396, 2011 | 130 | 2011 |
| TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2–breast cancer A Bardia, K Jhaveri, K Kalinsky, S Pernas, J Tsurutani, B Xu, E Hamilton, ... Future Oncology 20 (8), 423-436, 2024 | 21 | 2024 |
| Novel glutamine antagonist JHU395 suppresses MYC-driven medulloblastoma growth and induces apoptosis K Pham, MJ Maxwell, H Sweeney, J Alt, R Rais, CG Eberhart, BS Slusher, ... Journal of Neuropathology & Experimental Neurology 80 (4), 336-344, 2021 | 17 | 2021 |
| TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer RA Dent, DW Cescon, T Bachelot, KH Jung, ZM Shao, S Saji, TA Traina, ... Future Oncology 19 (35), 2349-2359, 2023 | 16 | 2023 |
| Modulation of Sp1 and Sp3 in lung epithelial cells regulates ClC-2 chloride channel expression KW Holmes, R Hales, S Chu, MJ Maxwell, PJ Mogayzel Jr, PL Zeitlin American journal of respiratory cell and molecular biology 29 (4), 499-505, 2003 | 16 | 2003 |
| Comprehensive metabolic profiling of myc-amplified medulloblastoma tumors reveals key dependencies on amino acid, tricarboxylic acid and hexosamine pathways K Pham, AR Hanaford, BA Poore, MJ Maxwell, H Sweeney, ... Cancers 14 (5), 1311, 2022 | 13 | 2022 |
| Unbiased proteomic and phosphoproteomic analysis identifies response signatures and novel susceptibilities after combined MEK and mTOR inhibition in BRAFV600E mutant glioma MJ Maxwell, A Arnold, H Sweeney, L Chen, TSM Lih, M Schnaubelt, ... Molecular & Cellular Proteomics 20, 2021 | 9 | 2021 |
| Dual mTORC1/2 inhibition compromises cell defenses against exogenous stress potentiating Obatoclax-induced cytotoxicity in atypical teratoid/rhabdoid tumors A Parkhurst, SZ Wang, TR Findlay, KJ Malebranche, A Odabas, J Alt, ... Cell Death & Disease 13 (4), 410, 2022 | 5 | 2022 |
| Abstract OT1-03-05: TROPION-Breast02: Phase 3, open-label, randomized study of first-line datopotamab deruxtecan versus chemotherapy in patients with locally recurrent … R Dent, DW Cescon, T Bachelot, KH Jung, ZM Shao, S Saji, TA Traina, ... Cancer Research 83 (5_Supplement), OT1-03-05-OT1-03-05, 2023 | 4 | 2023 |
| TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan±durvalumab in patients with triple-negative breast cancer and residual invasive disease at … A Bardia, L Pusztai, K Albain, EM Ciruelos, SA Im, D Hershman, ... Therapeutic Advances in Medical Oncology 16, 17588359241248336, 2024 | 3 | 2024 |
| OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In Vitro And In Vivo Glucose And Glutamine Usage K Pham, B Poore, A Hanaford, MJ Maxwell, H Sweeney, A Parthasarathy, ... Neuro-Oncology Advances 3 (Supplement_2), ii15-ii15, 2021 | 1 | 2021 |
| Abstract LB143: Improving treatment outcomes: a digital solution for remote patient monitoring of stomatitis for patients receiving Dato-DXd RH Wray, E Piault, L Miller-Potucka, JA Bell, R Fairhurst, SS Khan, ... Cancer Research 83 (8_Supplement), LB143-LB143, 2023 | | 2023 |
| TROPION-Breast03: Datopotamab deruxtecan (Dato-DXd)±durvalumab vs investigator's choice of therapy (ICT) for triple-negative breast cancer (TNBC) with residual disease … A Bardia, L Pusztai, K Albain, K Kalinsky, D Hershman, W Barlow, ... Breast, 2023 | | 2023 |
| COMPREHENSIVE PROTEOMIC PROFILING OF BRAFV600E GLIOMA CELLS SHOWS UPREGULATION OF GLYCOLYSIS AND TCA CYCLE PROTEINS AFTER COMBINED MTOR AND MAP KINASE PATHWAY BLOCKADE L Alaali, E Raabe, M Maxwell, C Eberhart, H Zhang NEURO-ONCOLOGY 24, 102-102, 2022 | | 2022 |
| Comprehensive metabolic profiling of high MYC medulloblastoma revealed key differences between in vitro and in vivo in glucose and glutamine usage KD Pham, B Poore, A Hanaford, MJ Maxwell, H Sweeney, ... Cancer Research 81 (13_Supplement), 2321-2321, 2021 | | 2021 |
| FSMP-18. COMPREHENSIVE METABOLIC PROFILING OF HIGH MYC MEDULLOBLASTOMA REVEALS KEY DIFFERENCES BETWEEN IN VITRO AND IN VIVO GLUCOSE AND GLUTAMINE USAGE K Pham, B Poore, A Hanaford, MJ Maxwell, H Sweeney, A Parthasarathy, ... Neuro-oncology Advances 3 (Suppl 1), i19, 2021 | | 2021 |
| Novel glutamine antagonist JHU-395 suppresses MYC-driven medulloblastoma growth and induces apoptosis K Pham, M Maxwell, H Sweeney, J Alt, R Rais, BS Slusher, CG Eberhart, ... Cancer Research 80 (16_Supplement), 510-510, 2020 | | 2020 |
| Glutamine antagonists synergize with L-asparaginase in MYCN-driven rhabdomyosarcoma MJ Maxwell, BA Poore, A Hanaford, J Alt, R Rais, BS Slusher, ... Cancer Research 79 (13_Supplement), 5277-5277, 2019 | | 2019 |
